articles

iBio’s transformation driven by FastPharming System, 3D bioprinting materials and proprietary therapeutics

iBio (NYSE American:IBIO) is continuing its transition from a licensing business to a manufacturing services provider and developer of proprietary biologics. Central to the initiative is a new ...

news

iBio Announces Collaboration with EdgePoint AI for Next Gen Quality in Biologics Manufacturing

NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc. ...

events

ARMI | BIOFABUSA SPRING SUMMIT: MEETING IN THE MILLYARD 2020

May 19-19, 2020
ARMI | BioFabUSA - THE TECHNOLOGY CENTER
Manchester, NY

Technology

Why FastPharming ?


FastPharming overcomes issues presented by mammalian expression systems:

  • Speed: Avoids lengthy clone selection and MCB establishment processes by "transfecting at scale"
  • Scale-up: Simple & easy - just plant more plants
  • Sustainability:  Truly "green" manufacturing - no plastic waste when a plant is the "single-use bioreactor"
  • Safety:  Reduced risk of viral contamination
  • Quality:  Accessible, flexible glycosylation controls
  • Cost:  Lower facility CapEx and OpEx in many cases
Learn More

Increased Speed-to-Market


iBio CDMO Services


Process Development

FastPharming optimizes gene-expression, glycosylation, and purification parameters to deliver a robust process for your APIs.

cGMP Manufacturing

The FastPharming system transfects at large-scale to easily and reliably deliver biologics in clinical trial or commercial quantities.

Aseptic Fill/Finish

In-line labelling allows serialization of vials and bottles for greater quality assurance of mAbs, viral vectors, and other biologics.

Bioanalytics

An experienced analytical staff provides method development and validation support with expertise in protein characterization using mass spectrometry.

Quality & Regulatory

Quality systems have been carefully constructed to meet cGMP requirements, and iBio can provide regulatory guidance given the team’s experience with therapeutic development.

Factory Solutions

When the time is right, iBio facilitates insourcing by designing and building your own environmentally sustainable FastPharming facilities.

Technology Applications


The FastPharming platform produces a variety of recombinant products including:

  • Biobetter and biosimilar antibodies
  • Antigens for subunit vaccine design
  • Virus-like particles (VLP)
  • Lysosomal enzymes
  • Blood factors and cytokines
  • Scaffolds, maturogens and materials for 3D Bioprinting and biofabrication

Contact Us

Interested in applying the power of FastPharming to your project?


iBio offers the CDMO capabilities needed to develop and deliver biologics to market - process development, scale-up, cGMP manufacturing, bioanalytical product characterization, aseptic fill/finish, and quality and regulatory support.

Send us a Message